Situated in Sydney’s Macquarie Park and built to pharmaceutical specifications, Recce and its experimental anti-infective formulations are produced in its wholly owned, automated manufacturing facility with existing output of 500 doses per hour at a 99.9% product yield.

Recce has demonstrated manufacturing quality and volume capabilities for RECCE® 327’s indicated first in-human clinical trials.

The U.S. Food and Drug Administration (FDA) awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

img 1
img 0 3
img 2

We have established a patented, automated, economical manufacturing process for our synthetic compounds. We have invested in a purpose built, wholly owned manufacturing facility, produced to the highest pharmaceutical standards.

Furthermore, the manufacturing process is reproducible and has a CMC (Chemistry, Manufacturing, and Controls) data package, essential for clinical study materials.

Recce Pharmaceutical’s synthetic process is efficient giving rise to a 99.9% product yield in several hours. It requires no specialised and expensive waste removal or risk of environmental contamination

product overview

Sign up for news and updates

Receive news and information direct to your inbox.